认知配准、软件辅助图像融合或磁共振引导下前列腺靶向穿刺活检的前列腺癌检出与并发症:比较研究的系统评价与荟萃分析
该系统评价与荟萃分析纳入20项比较研究共4928例患者,比较认知配准靶向活检(COG-TB)、MRI-超声融合靶向活检(FUS-TB)与磁共振引导下靶向活检(IB-TB)的临床显著前列腺癌(csPCa)检出率。结果显示三种方法csPCa检出率相当(COG-TB 0.37、FUS-TB 0.39、IB-TB 0.47),iPCa检出率亦相似,并发症报告较少且无统计学显著差异。作者认为技术选择可考虑资源可及性与操作者偏好,并需精心设计的前瞻性研究进一步明确。
要点
- 三种MRI靶向活检技术的csPCa检出率相当:COG-TB 0.37、FUS-TB 0.39、IB-TB 0.47。
- iPCa检出率亦相似:COG-TB 0.12、FUS-TB 0.17、IB-TB 0.18。
- 并发症报告不频繁,可获取数据中三种技术间无统计学显著差异。
核心结论
- 专注于比较研究的本分析表明,COG-TB、FUS-TB与IB-TB之间csPCa和iPCa检出率无显著差异。
- 技术选择可能超越诊断准确性,需考虑资源可及性与操作者偏好等因素。
- 需要精心设计的前瞻性研究以完善对不同临床场景下靶向活检最佳方法的理解。
研究设计与样本
- 系统评价与荟萃分析,检索PubMed、EMBASE、PubMed、Web of Science和Scopus数据库2014年至2023年的文献。
- 纳入至少比较两种靶向活检方法并报告csPCa检出率的研究,共20项研究、4928例患者纳入定量合成。
- 检出率采用随机效应模型合并,并计划按csPCa定义、阳性MRI、既往活检状态、活检路径、前列腺体积和病灶特征进行亚组敏感性分析。
主要发现
- csPCa检出率:COG-TB 0.37、FUS-TB 0.39、IB-TB 0.47,三者相当。
- iPCa(ISUP GG 1)检出率:COG-TB 0.12、FUS-TB 0.17、IB-TB 0.18,三种技术相似。
- 所有预计划的敏感性分析均未显示各靶向活检方法间csPCa检出率有统计学显著差异。
- 并发症发生率报告不频繁,可获取数据中未观察到各技术间有统计学显著差异。
临床怎么用
- 原文结论未据此给出具体推荐,仅指出技术选择可能需考虑资源可及性与操作者偏好。
- 作者认为需要精心设计的前瞻性研究以完善对不同临床场景下靶向活检最佳方法的理解。
局限性
- 并发症发生率报告不频繁。
- 需要精心设计的前瞻性研究以完善对不同临床场景下靶向活检最佳方法的理解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Three primary strategies for MRI-targeted biopsies (TB) are available: Cognitive TB (COG-TB), MRI-US Fusion TB (FUS-TB), and In Bore TB (IB-TB). Despite nearly a decade of practice, a consensus on the preferred approach is lacking, with previous studies showing comparable PCa detection rates among the three methods. METHODS: We conducted a search of PubMed, EMBASE, PubMed, Web of Science, and Scopus databases from 2014 to 2023, to identify studies comparing at least two of the three methods and reporting clinically significant PCa (csPCa) detection rates. The primary and secondary outcomes were to compare the csPCa and insignificant prostate cancer (iPCa, ISUP GG 1) detection rates between TB techniques. The tertiary outcome was to compare the complication rate between TB techniques. Detection rates were pooled using random-effect models. Planned sensitivity analyses included subgroup analysis according to the definition of csPCa and positive MRI, previous biopsy status, biopsy route, prostate volume, and lesion characteristics. RESULTS: A total of twenty studies, involving 4928 patients, were included in the quantitative synthesis. The meta-analysis unveiled comparable csPCa detection rates among COG-TB (0.37), FUS-TB (0.39), and IB-TB (0.47). iPCa detection rate was also similar between TB techniques (COG-TB: 0.12, FUS-TB: 0.17, IB-TB: 0.18). All preplanned sensitivity analyses were conducted and did not show any statistically significant difference in the detection of csPCa between TB methods. Complication rates, however, were infrequently reported, and when available, no statistically significant differences were observed among the techniques. CONCLUSIONS: This unique study, exclusively focusing on comparative research, indicates no significant differences in csPCa and iPCa detection rates between COG-TB, FUS-TB, and IB-TB. Decisions between these techniques may extend beyond diagnostic accuracy, considering factors such as resource availability and operator preferences. Well-designed prospective studies are warranted to refine our understanding of the optimal approach for TB in diverse clinical scenarios.
引用
- Falagario UG, Pellegrino F, Fanelli A, et al. Prostate cancer detection and complications of MRI-targeted prostate biopsy using cognitive registration, software-assisted image fusion or in-bore guidance: a systematic review and meta-analysis of comparative studies. Prostate Cancer Prostatic Dis. 2024. PMID: 38580833. doi:10.1038/s41391-024-00827-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。